Nuclear hormone receptors (NRs) are ligand-dependent, DNA-binding transcription factors that regulate gene expression and various physiological functions. The journey to understanding how NRs control gene transcription has been long and difficult. Initially, it was thought that NRs enabled general transcription factors and RNA polymerase II to assemble at the gene promoter to initiate mRNA synthesis. However, work began in the 1970s to search for nuclear non-histone helper proteins that were thought to aid the binding to DNA and the transcriptional function of NRs 1,2 . The findings that the activation of one overexpressed NR could indirectly inhibit the transcriptional activity of another NR 3, 4 and that in vitro transcription systems consisting of purified NRs and general transcription factors were inefficient further suggested that additional transcription activators were required for efficient hormone-induced transcriptional activation 5 . In 1995, steroid receptor co-activator 1 (SRC1, also known as NCOA1) was cloned as the first authentic NR co-activator. SRC1 was found to interact with steroid receptors in a hormone-dependent manner and robustly increase the transcriptional activities of steroid receptors 6 . Soon after, two other homologous proteins, SRC2 (also known as TIF2, GRIP1 and NCOA2) 7, 8 and SRC3 (also known as p/CIP, RAC3, AIB1, ACTR, TRAM1 and NCOA3) [9] [10] [11] [12] [13] , were characterized as NR coactivators. These three homologous proteins comprise the p160 SRC family. In this Review, we summarize current knowledge regarding the molecular features, functional mechanisms, post-translational modifications and physiological functions of the SRC family members. Our major emphasis is on the contributions and mechanisms of the SRC family in cancer.
Nuclear hormone receptors (NRs) are ligand-dependent, DNA-binding transcription factors that regulate gene expression and various physiological functions. The journey to understanding how NRs control gene transcription has been long and difficult. Initially, it was thought that NRs enabled general transcription factors and RNA polymerase II to assemble at the gene promoter to initiate mRNA synthesis. However, work began in the 1970s to search for nuclear non-histone helper proteins that were thought to aid the binding to DNA and the transcriptional function of NRs 1, 2 . The findings that the activation of one overexpressed NR could indirectly inhibit the transcriptional activity of another NR 3, 4 and that in vitro transcription systems consisting of purified NRs and general transcription factors were inefficient further suggested that additional transcription activators were required for efficient hormone-induced transcriptional activation 5 . In 1995, steroid receptor co-activator 1 (SRC1, also known as NCOA1) was cloned as the first authentic NR co-activator. SRC1 was found to interact with steroid receptors in a hormone-dependent manner and robustly increase the transcriptional activities of steroid receptors 6 . Soon after, two other homologous proteins, SRC2 (also known as TIF2, GRIP1 and NCOA2) 7, 8 and SRC3 (also known as p/CIP, RAC3, AIB1, ACTR, TRAM1 and NCOA3) [9] [10] [11] [12] [13] , were characterized as NR coactivators. These three homologous proteins comprise the p160 SRC family. In this Review, we summarize current knowledge regarding the molecular features, functional mechanisms, post-translational modifications and physiological functions of the SRC family members. Our major emphasis is on the contributions and mechanisms of the SRC family in cancer.
Structural and functional features of SRCs
SRCs contain three structural domains. The aminoterminal basic helix-loop-helix-Per/ARNT/Sim (bHLH-PAS) domain is the most conserved region and is required for protein-protein interactions [14] [15] [16] . The bHLH-PAS domain can interact with several transcription factors, such as myogenin, myocytespecific enhancer factor 2C (MEF2C) and transcriptional enhancer proteins, to potentiate transcription 17, 18 . The central region of the SRC proteins contains three LXXLL (in which X is any amino acid) motifs, which form amphipathic α-helices and are responsible for interacting with NRs [19] [20] [21] . The carboxyl terminus contains two transcriptional activation domains (AD1 and AD2). AD1 binds CREB-binding protein (CBP) and the histone acetyltransferase p300 (also known as EP300), and the recruitment of CBP or p300 by SRCs to the chromatin is essential for SRC-mediated transcriptional activation. AD2 interacts with co-activator-associated arginine methyl transferase 1 (CARM1) and protein arginine N-methyltransferase 1 (PRMT1), which are histone methyltransferases [22] [23] [24] [25] [26] [27] [28] [29] . The C termini of SRC1 and SRC3 contain HAT activity domains, although their cellular substrates are incompletely identified 12, 30 . These molecular features provide SRCs with a suitable structural base for recruiting additional coregulators and general transcription factors, which in turn results in chromatin remodelling, assembly of general transcription factors and recruitment of RNA polymerase II for transcriptional activation 31, 32 . The basic SRC structural domains and the simplified functional mechanisms for SRCs in NR-dependent transcriptional activation are outlined in FIG. 1 .
In addition to serving as co-activators for NRs, SRCs are co-activators for other transcription factors, including nuclear factor-κB (NF-κB), Smads, E2F1, signal transducers and activators of transcription (STATs), hypoxia inducible factor 1 (HIF1), p53 and RB (TABLE 1) . SRCs can also promote gene transcription by interacting with kinases, phosphatases, ubiquitin ligases, small ubiquitin-related modifier (SuMO) ligases, histone acetyltransferases and histone methyltransferases (TABLE 1) . By modulating gene expression that is controlled by a broad range of NRs and non-NR transcription factors, SRCs regulate many diverse physiological functions.
The molecular targets of SRCs are numerous. Genetic ablation of Src1 altered the gene expression patterns that are involved in cell cycle and energy metabolism pathways, such as glycolysis, glycogen synthesis and fatty acid synthesis 33 
. Genetic ablation of Src2 increased gene expression for energy expenditure but decreased gene expression for energy storage 33 . Src3 is required for the expression of several genes for the cell cycle and apoptosis in breast cancer cells 34 . Five alternatively spliced SRC1 isoforms have been reported 35 . In comparison to SRC1a, SRC1b lacks an N-terminal region, and SRC1c, SRC1d and SRC1e all differ from SRC1a (as well as from each other) at their C termini. It has been shown that SRC1a and SRC1b have different abilities to increase oestrogen receptor-α (ERα; also known as ESR1) activity in cultured cells 36 . A SRC3 isoform, AIB1-Δ3, has also been reported 37 . AIB1-Δ3 lacks the N-terminal bHLH-PAS domain and it may be a more active co-activator for ERα and progesterone receptor (PR; also known as PRGR) than the full-length SRC3. However, the in vivo expression profiles and physiological significance of these SRC1 and SRC3 isoforms are currently unclear.
Post-translational modifications of SRCs
The limiting concentrations of cellular SRCs suggest that changes in SRC levels and/or activities are efficient means for the cell to regulate gene expression. Several studies have demonstrated that signalling pathways that are activated by extracellular stimuli, such as hormones, growth factors and cytokines, induce multiple post-translational modifications of SRCs, including phosphorylation, ubiquitylation, sumoylation, acetylation and methylation (FIG. 2) . These dynamic and often reversible post-translational modifications have crucial roles in determining the protein stability, the transcription factor interaction specificity and the transcriptional activity of SRCs; they also link SRC functions and cellular responses to environmental cues. Deregulated post-translational modification of SRC molecules has significant implications in human diseases, such as cancer.
Phosphorylation. Phosphorylation of SRCs changes their affinity for specific NRs and modulates NR-dependent gene expression [38] [39] [40] [41] . Epidermal growth factor (EGF), interleukin 6 (IL-6) and cyclic AMP treatments stimulate proline-directed kinase phosphorylation of SRC1 on Thr1179 and Ser1185, and phosphorylated SRC1 has higher co-activator function in both liganddependent and ligand-independent NR pathways 39, 42 . Interestingly, EGF-induced phosphorylation of SRC1 increases PR-dependent transcription 39 , IL-6-mediated SRC1 phosphorylation promotes androgen receptor (AR; also known as ANDR)-dependent transcription in a ligand-independent manner 42 and cAMP-induced phosphorylation of SRC1 enables recruitment of p300 and CBP, as well as PR-dependent transcription, in a ligand-independent manner 43 . Furthermore, MAPKmediated phosphorylation of SRC1 on Thr1179 and Ser1185 increases its affinity for AR in prostate cancer cells, perhaps contributing to prostate cancer recurrence 42, 44 . In endometrial cancer cells, the oncogenic kinase SRC mediates SRC1 phosphorylation significantly increasing the agonist activity of tamoxifen, indicating
At a glance
• SRC1 was the first cloned steroid receptor co-activator that interacts with steroid hormone receptors to promote transcriptional activation in a hormone-dependent manner.
• The p160 SRC family contains three homologous members, SRC1, SRC2 and SRC3, that interact with nuclear receptors and specific transcription factors. They recruit chromatin remodelling and other transcriptional enzymes to facilitate the assembly of general transcription factors for transcriptional activation.
• SRCs are post-translationally modified in response to several upstream signalling pathways. These post-translational modifications determine or modulate SRC stability, subcellular localization, functional specificity, co-activator activity and/or co-activator complex assembly or disassembly.
• SRC-knockout mice show that SRCs are involved in many physiological processes and each SRC has both specific and redundant physiological functions in embryonic and adult tissues.
• SRC1 expression is increased in a subset of breast cancers and is positively correlated with ERBB2 positivity and poor disease-free survival rate. Knockdown of SRC1 in breast cancer cells inhibits cell proliferation.
• Knockout of Src1 in mouse mammary tumour virus (MMTV)-polyoma middle T (PyMT) mice suppresses metastasis without affecting primary tumour formation. SRC1 promotes breast cancer metastasis by upregulating ERBB2, colony stimulating factor 1 and TWIST1 expression.
• Both gene amplification and overexpression of SRC3 occur in a subset of breast cancers. SRC3 overexpression usually correlates with the expression of ERBB2, matrix metalloproteinase 2 (MMP2), MMP9 and polyoma enhancer activator 3, and with larger tumour size, higher tumour grade and/or poor disease-free survival.
• SRC3 has an important role in promoting breast tumour cell proliferation, migration, invasion and metastasis through many mechanisms, such as increasing the function of oestrogen receptor-α and E2F1, the activity of the insulin-like growth factor 1 (IGF1) signalling pathway, epidermal growth factor receptor (EGFR) and ERBB2, and the expression of MMPs.
• Knockout of Src3 in mice suppresses mammary tumour initiation, growth and metastasis, and overexpression of SRC3 in mouse mammary epithelial cells is sufficient to induce spontaneous mammary tumorigenesis.
• SRC3 expression is increased during prostate tumorigenesis in mice. Knockout of Src3 efficiently arrests prostate tumour progression at a well-differentiated stage.
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that SRC1 has a role in tamoxifen-induced endometrial proliferation and increases the risk of endometrial cancer that is associated with the use of tamoxifen 45, 46 . For SRC2, Ser736 is phosphorylated by MAPKs, including oestrogen-induced p38 and EGF-induced extra cellular signal-regulated kinases (ERKs). Phosphorylation of Ser736 increases the interaction of SRC2 with p300 and CBP and increases the SRC2 co-activation function for ERα, PR and AR 38, 44, 47 . Protein kinase A (PKA) also phosphorylates SRC2, resulting in a rapid increase in SRC2 co-activator activity followed by accelerated SRC2 degradation 48, 49 . In SRC3, seven Ser/Thr (Thr24, Ser505, Ser543, Ser601, Ser857, Ser860 and Ser867) phosphorylation sites and one Tyr (Tyr1357) phosphorylation site are functionally important 40, 41, 50 . The kinases that phosphorylate and activate SRC3 include MAPK, IKK, Akt (by inhibiting glycogen synthase kinase (GSK3α or GSK3β) and casein kinase 1 isoform delta (CK1δ; also known as KC1D), suggesting a role for SRC3 in accepting signals from multiple pathways. SRC3 is also a target of the ABL tyrosine kinase that can be activated by oestrogen and growth factors. Phosphorylation of Tyr1357 by ABL facilitates SRC3 action in mediating ERα, PR and NF-κB-dependent transcription by increasing SRC3 binding to p300 and transcription factors 50 . Importantly, Tyr1357 phosphorylation is increased in ERBB2-induced mouse breast tumours, suggesting that phosphorylation of Tyr1357 has a role in oncogenesis. Moreover, the level of Tyr1357 phosphorylation might serve as a marker for evaluating the efficacy of tyrosine kinase inhibitors.
Clinical studies have shown that SRC3 expression levels are increased in a subset of breast tumours, and high SRC3 levels are commonly associated with ERBB2 expression, tamoxifen resistance, disease recurrence and poor prognosis [51] [52] [53] . This unfavourable outcome can be explained by a series of linked molecular events. ERBB2 expression activates MAPK and Akt and causes phosphorylation of SRC3 and ER, resulting in transcriptional activation and cell proliferation. Furthermore, Akt can stabilize SRC3 by inhibiting GSK3 (REF. 54 ), suggesting a positive-feedback mechanism between SRC3 levels and Akt activity. Akt overactivation is frequently observed in human cancers.
Interestingly, SRC3 function and cellular concentrations are counter-regulated by kinases and phosphatases. Pyridoxal phosphatase (PDXP) and protein phosphatase 2A (PP2A) dephosphorylate SRC3, inhibit SRC3 interaction with ERα and reduce SRC3 co-activator activity 55 . Protein phosphatase 1 (PP1) dephosphorylates phosphorylated Ser101 and Ser102, which decreases SRC3 transcriptional activity and increases SRC3 stability 55 (FIG. 2) . By contrast, atypical protein kinase C (aPKC)-mediated SRC3 phosphorylation stabilizes SRC3 by targeting an acidic region of amino acid residues 1031-1097, preventing SRC3 from interacting with the C8 subunit of the 20S core proteasome 56 . As both aPKC and SRC3 are frequently overexpressed in cancers, they may synergistically promote carcinogenesis.
The transcriptional activities of SRCs are also regulated by subcellular localization and intracellular trafficking. SRCs contain nuclear import and export signals and localize in both the cytoplasm and the nucleus [57] [58] [59] . Post-translational modifications can alter the availability of SRCs in a subcellular compartment by regulating their nucleocytoplasmic trafficking. For example, tumour necrosis factor-α (TNFα)-and EGF-induced phosphorylation of SRC3 causes its redistribution from the cytoplasm to the nucleus 60, 61 . In the cytoplasm, oestrogen-induced SRC3 phosphorylation leads to SRC3 and ERα interaction, suggesting that activation of SRC3 may have a role in oestrogen-induced nongenomic effects 62 . SRC3 is also associated with, and phosphorylated by, IKK and ABL in the cytoplasm in response to TNFα or growth factor stimulation, indicating a role for SRC3 in these kinase-driven pathways 50, 61 . Furthermore, SRC3 can interact with TIA1 and TIAR, two translational repressors associated with Au-rich regions in the 3′ untranslated region of cytokine mRNAs in the cytoplasm, thereby inhibiting translation of IL1, IL6 and TNFα mRNAs 63 .
Ubiquitylation. 26S proteasome-mediated degradation regulates the function of NRs and the turnover of activated NRs and SRCs [64] [65] [66] [67] [68] . Recently, two Skpl-cullin-F box protein (SCF)-dependent monoubiquitylation sites (Lys723 and Lys786) in the NR interaction domain of SRC3 were identified 54 . Phosphorylation of Ser505 by GSK3 and Ser860 by p38 MAPK not only increases the interaction of SRC3 with ER and AR but also regulates its ubiquitylation and protein stability 54, 69 . The sequential and allow SRCs to be recruited to the enhancer region of the NR target genes. SRCs further interact with cyclic AMP response element-binding protein (CBP), p300 (a 300 kDa protein homologous to CBP; also known as EP300), p300 and CBP-associated factor (PCAF), co-activator-associated arginine methyltransferase 1 (CARM1) and protein arginine N-methyltransferase 1 (PRMT1), and recruit these common co-activators to the chromatin to build up a steroid receptor-directed transcriptional activation complex. This protein complex uses its protein acetyltransferase and methyltransferase activities to remodel the chromatin structure and to facilitate the assembly of general transcription factors and RNA polymerase II (Pol II) on the promoter for transcriptional activation. Of note, in addition to the interactions between NR and the NR interaction domain of SRCs, interactions between NR and the basic helix-loop-helix-Per/ARNT/Sim (bHLH-PAS) domain of SRCs have been documented and may be important for function (see dotted line with arrowheads). AD, activation domain; GTF, general transcription factor; L, LXXLL motif; NRID, nuclear receptor interaction domain; Q, glutamine-rich region; S/T, serine and threonine-rich domain; TAFIIs, TBP-associated general transcription factors; TBP, TATA-binding protein.
phosphorylation-dependent monoubiquitylation to polyubiquitylation couples transcriptional activation with SRC3 degradation, ensuring a proper termination of transcription (FIG. 2) . In contrast to GSK3-mediated phosphorylation that causes SRC3 degradation, aPKCmediated SRC3 phosphorylation protects SRC3 from proteasomal degradation in an ERα-dependent manner, leading to increased oestrogen-induced breast cancer cell growth 56 . Although the structure of small ubiqitin-related modifier (SuMO) is similar to ubiquitin, the fate of a sumoylated protein is usually distinct from that of a ubiquitylated protein. Sumoylation can either antagonize SRC ubiquitylation by targeting a common lysine substrate to prevent its degradation and increase its concentration or can induce the SRCs to adopt an inactive conformation [70] [71] [72] [73] [74] [75] [76] (FIG. 2) . In addition to ubiquitin-dependent turnover, PSME3 (a proteasome activator that stimulates the trypsin-like activity of the 20S proteasome) binds and promotes SRC3 degradation in a ubiquitin-and ATP-independent manner 77 .
Acetylation and methylation.
The function of SRCs can be modulated by acetylation. After transcriptional initiation, SRC3 is acetylated by p300 and CBP, resulting in the disassembly of the NR and SRC3 complex and termination of transcription 78 (FIG. 2) . After initial stimulation, oestrogen treatment increases CARM1-mediated SRC3 methylation on Arg1171 and terminates transcription by disassembling the SRC3 co-activator complexes 79 and increasing SRC3 degradation 80 
(FIG. 2).
Combined post-translational modifications. Different combinations of post-translational modifications determine the co-activator potency and selectivity of the SRCs and allow them to integrate multiple upstream signals into a finely tuned regulation of gene expression. For example, retinoic acid-and p38 MAPK-induced SRC3 phosphorylation initially increases SRC3 interaction with retinoic acid receptor-α (RARα) to activate transcription. Subsequently, phosphorylated SRC3 is subjected to ubiquitylation and degradation, thereby leading to transcriptional termination. Another study demonstrated that phosphorylation of SRC3 on Ser509 primed it for phosphorylation on Ser505. This then triggered SRC3 monoubiquitylation and subsequent polyubiquitylation, which are responsible for the activation and degradation of SRC3, respectively 54 
Oestrogen-induced MAPK-dependent SRC3 phosphorylation inhibited SRC3 sumoylation; conversely, dephosphorylation increased SRC3 sumoylation and decreased SRC3 activity 76 . As ubiquitylation and sumoylation can occur on the same lysine residue, different phosphorylation codes may determine whether SRC3 is ubiquitylated or sumoylated, methylated or acetylated. As post-translational modifications influence both the cellular concentrations and the co-activator activities of SRCs, interventions that modulate the post-translational modification of the SRCs have the potential for controlling the detrimental roles of overexpressed SRCs in cancer.
In vivo functions of SRC family members Our knowledge of the diverse in vivo functions of the SRC family is primarily gleaned from the characterization of knockout-mouse models
. These studies indicate that each SRC family member has specific physiological functions. However, the additive severity of the phenotypes observed in double-knockout mice indicates the presence of certain cooperative physiological functions among SRC family members. Most Src1
-/-mice do not survive and both male and female Src1 
;Src3
-/-mice die before birth, and mice that do survive exhibit compromised regulation of select peroxisome proliferator-activated receptor-γ (PPARγ) target genes that are involved in adipogenesis and mitochondrial uncoupling. These mice also have a higher leptin level, a developmental arrest in interscapular brown fat and a defect in adaptive thermogenesis. As a result, they eat more but are lean and resistant to obesity induced by a high-fat diet owing to a high basal metabolic rate and increased physical activity 82 .
SRC genes in cancer
Each SRC has been found to be overexpressed in many types of human cancer, and in steroid hormonepromoted breast and prostate cancers in particular.
Amplification of SRC1 or SRC2 is rare in cancer, but SRC3 on human chromosome 20q21 is more frequently amplified (TABLES 2-4). The precise mechanisms that underlie overexpression of SRCs in human cancer are still unclear. Many studies have investigated the mechanisms through which SRCs promote carcinogenesis and indicate that SRCs have important and distinct roles in promoting cancer initiation, progression and metastasis through alterations of multiple signalling pathways (FIG. 3) .
SRC expression and function in breast cancer
In normal human breast tissue, the levels of the three SRC proteins in epithelial cells are variable, but they are usually low or undetectable as assayed by immunohistochemistry [83] [84] [85] [86] [87] [88] . Several studies examined the expression profiles of SRC mRNA and protein levels in human breast tumours and these data are discussed below together with data from mouse models and cell lines.
SRC1.
Several studies have demonstrated that SRC1 is significantly increased in 19% to 29% of breast tumours [83] [84] [85] [86] . More importantly, this increase in SRC1 levels positively correlates with ERBB2 expression, lymph node metastasis, disease recurrence and poor disease-free survival (DFS) [83] [84] [85] (TABLE 2) . Interestingly, a recent clinical study revealed that increased SRC1 levels are an excellent independent predictor of breast cancer recurrence following therapy 89 .
In vitro, SRC1 has a role in cancer cell proliferation and invasion through multiple pathways. In MCF-7 breast cancer cells, SRC1 overexpression potentiates cell growth that is stimulated by oestrogen in accordance with an increase in the expression of oestrogen-responsive genes, indicating that SRC1 plays an important part in oestrogen receptor-mediated cell growth 90 . By contrast, reduction of SRC1 levels in MCF-7 cells decreases oestrogen-dependent DNA synthesis and also reduces the expression of the oestrogen-responsive pS2 gene 91 . Interestingly, MuC1, an ERα-interacting protein that is overexpressed in breast carcinomas, can stimulate ERα-mediated transcription by aiding SRC1 recruitment to oestrogenresponsive promoters, suggesting that SRC1 functions in MuC1-stimulated cell growth 92 . Furthermore, MCF-7 cells lacking SRC1 do not show increases in oestrogen-induced CXCL12 (also known as SDF1) expression and cell proliferation and invasion, suggesting that SRC1 may regulate cell proliferation and invasion through autocrine or paracrine activity of the CXCL12-CXCR4 signalling pathway 93 . In mouse mammary tumour virus (MMTv)-polyoma middle T (PyMT) mammary tumour-prone mice, SRC1 levels are increased during tumorigenesis. Knockout of Src1 does not affect PyMT-induced mammary tumour initiation and growth, but it helps to maintain epithelial differentiation and polarity and, importantly, prevents tumour cell metastasis to the lung. Further analyses revealed that SRC1 deficiency reduced ERBB2 expression and Akt activation and also inhibited colony stimulating factor 1 (CSF1) expression and
Box 1 | SRC-knockout mice
Although Src1 -/-mice display no gross defects in development and growth, careful analyses revealed that SRC1 has important in vivo roles in organ physiology. In reproductive organs, SRC1 deficiency reduces oestrogen-induced uterine growth, oestrogen-and progesterone-dependent uterine decidual response, mammary gland ductal side branching and alveolar formation, and testosterone-stimulated prostate growth 139 . In addition to their partial resistance to sex steroids, partial resistance to thyroid hormone exists in Src1 -/-mice 140, 141 . In the liver, SRC1 is an essential co-activator for CAAT/enhancer binding protein-α, which together with peroxisome proliferatoractivated receptor-γ (PPARγ) regulates the pyruvate carboxylase gene, which encodes the limiting enzyme for gluconeogenesis. In brown fat, activation of PPARγ triggers the recruitment of a co-activator complex containing PPARγ co-activator 1α (PPARGC1α), SRC1, CREB-binding protein and p300 (also known as EP300) 142 ; inactivation of SRC1 impairs the thermogenic activity of PPARGC1α, decreasing energy expenditure and resulting in obesity with a high-fat diet 143 .
Assessment of Src2
-/-mice demonstrated an important function of SRC2 in reproductive organs and in the regulation of metabolism. Src2 -/-Sertoli cells are unable to support normal spermatogenesis 144 and SRC2 is the dominant member of the SRC family that mediates androgen receptor function in the testis 145 . The hypofertility of female Src2 -/-mice is partially due to a placental hypoplasia 144 , and specific ablation of Src2 in the progesterone receptor-positive cell lineage inhibits the progesteroneinduced decidual response and causes a block in embryo implantation. Src2 ablation also results in reduced ductal side branching and alveologenesis in the mammary gland 137 . In white adipose tissue, SRC2 deficiency increases leptin expression and decreases the expression of genes responsible for anti-lipolysis as well as fatty acid uptake and trapping. In brown adipose tissue, SRC2 deficiency increases levels of uncoupling protein 1, PPARGC1α and acetyl CoA oxidase, promoting energy expenditure. As a result, Src2 -/-mice exhibit a higher body temperature under cold conditions, less fat accumulation, lower levels of fasting glycaemia and triglycerides, and higher insulin sensitivity 143 . In the liver, SRC2 increases retinoic acid receptor-related orphan receptor-α (RORα)-mediated glucose-6-phosphatase expression to regulate fasting hepatic glucose release from the liver. Src2 ablation recapitulates the human syndrome of Von Gierke's disease (also known as glycogen storage disease 1a) 146 .
Src3
-/-mice show growth retardation, delayed puberty, reduced female reproductive function and blunted mammary gland development 147, 148 . In agreement with the growth retardation, circulating insulin-like growth factor 1 (IGF1) levels in Src3 -/-mice are significantly reduced. SRC3 is required for vitamin D receptor-mediated expression of IGF1-binding protein 3, which maintains IGF1 stability in the circulation 149 . In the mammary gland, SRC3 deficiency decreases oestrogen-and progesterone-induced mammary ductal growth and alveologenesis, revealing the role of SRC3 in oestrogen receptor and progesterone receptor function 147 . SRC3 is not required for castration-induced regression and testosterone-stimulated regeneration of the prostate in mice, suggesting that SRC3 is not essential for androgen-and androgen receptor-dependent prostate morphogenesis 118 . 
Pituitary isograft
Implantation of a pituitary gland isolated from a syngeneic donor mouse into the kidney capsule of a recipient mouse. On stimulation of the implanted pituitary isograft, the recipient mouse shows significantly increased levels of prolactin, progesterone and oestradiol. macrophage recruitment to the tumour site 94 . In addition, a recent study demonstrated that SRC1 promotes epithelial-mesenchymal transition, migration, invasion and metastasis of mammary tumour cells by co-activating polyoma enhancer activator 3 (PEA3)-mediated TwIST1 expression 95 .
SRC2.
One study reported no significant change in the levels of SRC2 in breast tumours, and another study reported the correlation of SRC2 with cyclin D1 expression in ERα + breast tumours 86, 96 (TABLE 3) . In MCF-7 breast cancer cells, knockdown of SRC2 reduces oestrogeninduced cell proliferation and target gene expression 91 . Similar to SRC1 overexpression, SRC2 overexpression may promote cell proliferation and invasion through the induction of CXCL12 expression 93 .
SRC3.
In separate studies of breast tumours, the frequencies of SRC3 amplification were 9.5% as measured by fluorescent in situ hybridization 11 (TABLE 4) . In tamoxifentreated patients, high levels of SRC3 expression are associated with tamoxifen resistance and a poorer DFS. Importantly, patients with high levels of both SRC3 and ERBB2 exhibit early and severe resistance to therapy with selective oestrogen receptor modulators 52 . As ERBB2 activates MAPK, which in turn phosphorylates ER and activates SRC3 (REF. 100 ), the overexpression of both ERBB2 and SRC3 significantly increases the agonist activity of tamoxifen and therefore reduces its anti-tumour activity in patients with breast cancer 101 .
In breast cancer cells, SRC3 can be recruited to the oestrogen-responsive CCND1 promoter to increase cyclin D1 expression 102 -depletion of SRC3 in MCF-7 cells significantly reduces oestrogen-mediated cell proliferation and survival. Downregulation of SRC3 in MCF-7 cells also reduces oestrogen-dependent colony formation in soft agar and tumour growth in nude mice 103 .
The in vivo role of SRC3 in breast cancer initiation and progression has been investigated in multiple mouse models. In mice harbouring the MMTV-v-ras transgene (referred to as ras), breast tumour incidence was reduced dramatically in Src3 -/-;ras virgin mice and inhibited completely in ovariectomized Src3 -/-;ras mice 104 . Breast tumour latency and growth were delayed significantly in Src3 -/-;ras virgin mice with natural oestrous cycles, multiparous mice with cyclically increased reproductive hormones and virgin mice bearing pituitary isografts resulting in persistently increased hormone levels. Interestingly, SRC3 deficiency did not alter the expression of oestrogen-and progesterone-responsive genes in the mammary gland and tumours, but it caused partial resistance to insulin-like growth factor 1 (IGF1) because of a significant reduction in insulin receptor substrate 1 (IRS1) and IRS2. The impaired IGF1 signalling pathway in Src3 -/-;ras mammary epithelium and tumour cells may be partly responsible for the suppression of mammary tumorigenesis and metastasis.
In a second model, the role of SRC3 in the susceptibility of the mammary gland to chemical carcinogens was characterized 105 . This study demonstrated that mammary ductal outgrowths emanating from the Src3 -/-mammary epithelial transplants in wild-type mice were attenuated, indicating that the role of SRC3 in mammary ductal growth is autonomous of mammary epithelial cells. In mice treated with the chemical carcinogen DMBA, SRC3 deficiency protected the mammary gland, but not the skin, from tumorigenesis. In this model, SRC3 deficiency also suppressed the upregulation of both IRS1 and IRS2 and thereby inhibited the activation of Akt, the expression of cyclin D1 and cell proliferation.
In a third model, the role of SRC3 in breast tumorigenesis was assessed in MMTV-Erbb2-induced mammary tumorigenesis in wild-type and Src3-knockout mice 106 . This study showed that ERBB2-induced mammary tumour development was significantly delayed in Src3 +/-mice and completely suppressed in Src3 -/-mice. Compared with tumours from Src3 wild-type;Erbb2 mice, tumours from Src3 +/-;Erbb2 mice exhibited a In general, phosphorylation results in the activation of SRCs. In the case of SRC3, phosphorylation determines the selectivity of SRC3 for different transcription factors, promotes sequential ubiquitylation of SRC3 from monoubiquitylation (activation) to polyubiquitylation (degradation), and controls the duration of transcriptional activation by SRC3. Conversely, de-phosphorylation by a phosphatase (PPase) promotes SRC3 sumoylation, stabilizes SRC3 and inhibits SRC3 activity. Depending on the specific kinases and phosphorylation sites, phosphorylation could either increase or decrease SRC3 stability and cellular levels. Sumoylation increases SRC1 and SRC2 activities (the question mark indicates that the conclusion is based on a limited amount of data), but it inhibits SRC3 activity. SRC3 acetylation and methylation cause a disassembly of the transcription complex and promote transcriptional termination. Ac, acetyl; HAT, histone acetyl transferase; Me, methyl; P, phosphate; S, small ubiquitin-related modifier; Ub, ubiquitin.
decrease in phosphorylated ERBB2, cyclin D1 and cyclin E, reduced activity of Akt and JuN N-terminal kinase, and decreased cell proliferation. These findings suggest that SRC3 is required for ERBB2 oncogenic activity and that SRC3 reduction in the mammary epithelium should potentiate therapies aimed at inhibiting ERBB2 signalling in breast cancer 106 . In a fourth model, the role of SRC3 in breast cancer metastasis was investigated by using MMTv-PyMT mice 88 . This study demonstrated that genetic ablation of Src3 in MMTv-PyMT mice significantly reduced lung metastasis and the effect was cell autonomous. Cellular and molecular analyses revealed that SRC3 interacted with PEA3 and directly increased the activity of the Mmp2 and Mmp9 promoters as well as the expression of MMP2 and MMP9 in wild-type Src3;PyMT tumour cells. Therefore, SRC3 can aid breast cancer metastasis through MMP2-and MMP9-mediated epithelial-mesenchymal transition and cell invasiveness. This correlates with data from human breast tumours in which SRC3 expression is associated with high PEA3, MMP2 and MMP9 expression levels 88 . Finally, and importantly, the oncogenic role of SRC3 overexpression in the mammary gland was directly demonstrated by generating and characterizing MMTV-Src3 transgenic mice. This study showed that SRC3 overexpression caused mammary hypertrophy, hyperplasia, abnormal post-weaning involution and the spontaneous development of malignant mammary tumours. Tumour incidence was increased in other organs, including the pituitary and uterus 107 . In agreement with the downregulation of the IGF1 signalling pathway in Src3 -/-;ras mammary tumours 104 , SRC3 overexpressioninduced mammary tumours have a hyperactive IGF1 signalling pathway 107 . In summary, consensus results indicate that both SRC1 and SRC3 are overexpressed in a subpopulation of breast cancers without clear relevance to ER and PR expression. Overproduction of SRC1 and SRC3 is generally detrimental to patients. SRC2 expression profiles in breast cancer are less conclusive owing to a lack of sufficient data. Data from mouse models and cell lines indicate that SRC1 and SRC3 have important functions in breast cancer, including tumour initiation and progression. Data from SRC3 mouse models highlight the oncogenic nature of this protein when its expression is deregulated.
Prostate cancer
The expression profiles of SRC family members have been investigated in prostate tumours (TABLES 2-4). Amplification of SRC1 is rare in human tumours, and one study reported that SRC1 was amplified in only 2 out of 70 specimens that included prostate cancer cell lines, xenografts and primary tumours 108 . However, several studies have found that the expression levels of both SRC1 mRNA and SRC1 protein are positively correlated with prostate tumour grades [109] [110] [111] . In addition, one study found more nucleus-localized SRC1 in androgen-independent prostate tumours 108 , whereas another study using quantitative reverse transcription PCR failed to detect significant correlations between SRC1 mRNA and prostate tumour progression 112 . Overall, SRC1 is thought to be increased in certain prostate tumours, but its overexpression frequency has not been accurately determined.
In prostate cancer cells, SRC1 can increase AR-mediated cell proliferation in culture. SRC1 knockdown inhibits the proliferation of androgen-dependent LNCaP cells in culture. More interestingly, SRC1 knockdown inhibits the growth of C4-2 prostate cancer cells that depend on AR for growth in androgen-depleted medium 109 . However, reduction of SRC1 expression levels has no effect on the growth of the AR-negative PC-3 and Du145 prostate cancer cells 109 . These results suggest that SRC1 promotes prostate cancer growth by increasing AR function in both an androgen-dependent and an androgen-independent manner.
The role of SRC1 in prostate cancer has been investigated in vivo in transgenic adenocarcinoma of mouse prostate (TRAMP) mice harbouring the Sv40 large and small T antigen transgenes driven by a probasin promoter 113 . During prostate carcinogenesis, SRC1 levels remained constant in prostate tumours of TRAMP mice.
Src1
-/-TRAMP mice exhibited similar prostate tumour initiation, progression and metastasis to that observed in wild-type Src1 TRAMP mice. Interestingly, in both wild-type and Src1 -/-TRAMP mice, prostate carcinogenesis induced SRC3 overexpression. Therefore, the role of SRC1 in murine prostate carcinogenesis may be nonessential owing to possible compensations from SRC3 or overexpression of other co-activators.
SRC2 expression in prostate tumours has been found to be increased but the frequency of SRC2 overexpression has not been well characterized. It was reported that SRC2 expression in a subgroup of prostate cancers was positively associated with high tumour cell proliferation, high tumour grade and/or disease recurrence 110, 114 . In AR-positive prostate cancer cells, high levels of androgens repress SRC2 expression. Depletion of SRC2 reduces AR target gene expression and inhibits proliferation of AR-dependent and AR-independent prostate cancer cells, suggesting that SRC2 also increases prostate cancer cell growth through both AR-dependent and AR-independent pathways 114 . SRC3 expression in prostate tumours has been examined in two studies. One study, with a small number of samples, found that SRC3 was overproduced in 38% of tumour samples 115 . The other study, with a large number of tumour samples, found that SRC3 levels were positively correlated with increasing prostate-specific antigen levels, indicating tumour recurrence, Akt activation and tumour cell proliferation 116 . In prostate cancer cells, SRC3 activates the Akt-mTOR signalling pathway and stimulates cell growth by increasing cell size. SRC3 knockdown decreases cancer cell proliferation and xenograft tumour growth in nude mice and increases apoptosis 116, 117 . The role of SRC3 in spontaneous prostate cancer was investigated by comparing tumour initiation and progression in TRAMP and Src3 -/-TRAMP mice 118 . SRC3 was non-essential for normal androgen-AR-dependent prostate growth, and high levels of SRC3 expression were found in stromal and basal cells but not in luminal epithelial cells. Of note, high levels of SRC3 expression were detected in prostate tumour cells during progression towards more malignant stages. In agreement with this finding, the development of prostate epithelial hyperplasia and the initiation of well-differentiated tumours were not affected by the loss of SRC3. However, SRC3 loss efficiently arrested prostate tumour growth and progression at the well-differentiated stage and significantly extended the survival of the TRAMP mice 118 . These results indicate that de novo induction of SRC3 expression in partially transformed epithelial cells is essential for the progression of prostate tumorigenesis into poorly differentiated carcinoma. Inhibition of SRC3 expression or function in the prostate epithelium may be a potential strategy to suppress prostate cancer progression. Taken together, these findings suggest that overexpressed SRC family members have detrimental roles in the promotion of prostate cancer initiation and progression.
Other cancers
The expression profiles of SRC family members in other types of cancers are summarized in TABLES 2-4. Briefly, in colorectal cancer high levels of SRC3 were detected in 35% of tumours and were positively associated with tumour grades 119 . In endometrial carcinoma, one study reported an increase in SRC1 and SRC2 mRNAs 120 , although another study reported a decrease in SRC1 (REF. 121 ). SRC3 mRNA and protein levels were found to be increased in endometrial carcinomas, and various overexpression frequencies were reported in different studies 99, 120, 122 . SRC3 overexpression was detected in 46% of oesophageal squamous cell carcinomas and 40% of gastric cancers, and SRC3 expression levels were positively associated with higher cell proliferation, metastasis and poor prognosis 123, 124 . upregulated SRC3 was found in 64% of high-grade ovarian cancer specimens and 65% of pancreatic cancer specimens; SRC3 levels in these cancers were positively correlated with disease severity 125, 126 . An abnormal chromosomal rearrangement of inv(8) (p11p13) has been identified in a subset of patients with acute myeloid leukaemia 127, 128 . This rearrangement results in a fusion between the 5′ portion of MOZ mRNA and the 3′ portion of SRC2 mRNA; the fusion encodes a transcriptional activator domain that binds nucleosomes through MOZ and recruits CBP through a SRC2 domain [127] [128] [129] . MOZ-SRC2-transduced myeloid progenitors can be continuously passaged in culture and induce acute myeloid leukaemia in vivo 130 . These findings reinforce the concept that deregulation of a transcriptional co-activator can lead to malignant disease in humans.
Intriguingly, one study reported that SRC3 could inhibit IκB kinase to stabilize IκB and suppress NF-κB activation in the lymphoid lineage 131 . Genetic ablation of SRC3 resulted in the release of IκB kinase inhibition and constitutive NF-κB activation. Consequently, lymphocyte proliferation was activated in a subset of old Src3 -/-mice, which then developed spontaneous β-cell lymphoma 131 . Another study demonstrated that SRC3 deficiency in macrophages did not affect NF-κB-mediated gene transcription, but inhibited the production of proinflammatory cytokines such as IL-1, IL-6 and TNFα at the translational level 63 . It is currently unknown whether the increased inflammatory cytokines in Src3 -/-mice are partly responsible for the development of β-cell lymphoma. Taken together, these findings suggest that SRC3 regulates cell proliferation in a cellular and signalling context-dependent manner, ranging from proliferative and tumorigenic effects in most endocrine target organ epithelial cells to paradoxical antiproliferative effects in lymphoid cells.
Overall, one can conclude that miss-expression of SRC family members occurs not only in steroid hormone-promoted breast and prostate cancers but also in steroid-independent cancers, suggesting that SRC family members promote carcinogenesis through both steroid-dependent and steroid-independent pathways.
Summary and perspectives
Since SRC1 was identified as an NR co-activator in 1995 (REF. 6 ), the NR coregulator field has experienced an explosive increase in research aimed at understanding the mechanism of NR co-activator function, much of which has been applied to studies of hormone-related cancers. Emanating from these studies, many previously unknown proteins such as SRCs, metastasis-associated gene 1 and PPARγ co-activator 1α have been found to be 'master genetic regulators' 2 . In this Review, we have summarized present knowledge about the molecular features, post-translational modifications (FIG. 2) , interacting proteins (TABLE 1) , molecular targets and physiological functions of SRCs. SRCs coordinate the expression of many genes directed towards accomplishing physiological goals by interacting with and co-activating most NRs, as well as certain other transcription factors. Importantly, overexpression of SRC3 in mammary epithelial cells has been shown to be sufficient to induce spontaneous mammary tumours in mice, indicating that overexpression of SRC3 is oncogenic 107 . Accordingly, knockout of Src3 in mice suppresses oncogene-and carcinogen-induced breast cancer initiation, progression and metastasis 88, [104] [105] [106] . However, knockout of Src3 inhibits only prostate cancer progression and metastasis in TRAMP mice -it does not affect the initiation of prostate tumorigenesis 118 . Interestingly, knockout of Src1 suppresses mammary tumour metastasis without affecting primary tumour formation and does not affect prostate cancer initiation and progression 94, 95 , suggesting differing contributions from SRC1 and SRC3.
Many studies have investigated the mechanisms responsible for the promotion of carcinogenesis by SRCs. These studies have revealed that SRC1 can increase the expression of ERBB2, CSF1 and TwIST1 to promote breast cancer metastasis 94, 95 . SRC3 overexpression can increase v-ras-mediated cell transformation In general, SRCs increase steroid receptor functions and facilitate hormonal promotion of breast, prostate and ovarian cancers. Specifically, SRC1 increases ETS2-mediated ERBB2 expression and polyoma enhancer activator 3 (PEA3)-mediated TWIST1 expression and upregulates colony stimulating factor 1 (CSF1) expression to promote breast tumour cell migration, invasion and metastasis. A MOZ-SRC2 fusion gene causes acute myeloid leukaemia (AML). SRC3 upregulates its own expression by serving as a co-activator for E2F1 and SP1. The overexpressed SRC3 increases PEA3 and AP1-mediated matrix metalloproteinase (MMP) expression to promote breast and prostate tumour cell metastasis. SRC3 also increases E2F1-mediated cell cycle progression and GRB2-associated-binding protein 2 (GAB2) expression, which activates Akt. In addition, SRC3 upregulates insulin-like growth factor 1 (IGF1), insulin receptor substrate 1 (IRS1) and IRS2 to promote the IGF1 signalling pathway and to activate epidermal growth factor receptor (EGFR) and ERBB2. Activation of EGFR and ERBB2 increases Akt and MAPK activities, resulting in hyperactivation of Akt and MAPK, which contribute to cancer cell proliferation, growth, survival, migration, invasion and metastasis. AR, androgen receptor; ER, oestrogen receptor; PR, progesterone receptor. and activate ERα, EGFR and cyclin D1 expression as well as the Akt pathway, MMPs and focal adhesion kinase to promote tumour initiation, growth and metastasis 88, 102, [104] [105] [106] 117, 132, 133 . Although progress has been made in understanding the function of SRCs in various cancers and the molecular mechanisms by which SRCs influence carcinogenesis, important questions remain to be addressed. First, the molecular mechanisms responsible for SRC1 and SRC3 gene amplification and mRNA overexpression in cancers are still not fully understood. A limited number of studies have suggested that increased SRC3 levels in cancers might be attributable to both transcriptional activation and post-translational stabilization. On the one hand, SRC3 serves as a co-activator for E2F1, which drives cell proliferation 134, 135 . Both E2F1 and SRC3 can be tethered to the proximal region of the SRC3 gene promoter by interacting with SP1, which increases SRC3 mRNA transcription. In this manner, E2F1 and SRC3 form a positive regulatory loop that can constitutively increase SRC3 overexpression in cancer cells 136 (FIG. 3) .
On the other hand, regulation of SRC3 protein stability by post-translational modifications represents another important mechanism for increasing SRC3 levels in cancer (reviewed in preceding sections). Further investigations of the molecular mechanisms responsible for the miss-expression of SRC3 and other SRC family members may provide approaches to reprogramme their expression levels for cancer therapy.
Second, although some genes that are important for carcinogenesis and metastasis have been identified as SRC-regulated genes, a complete catalogue of the direct targets of SRCs in cancer cells is still unavailable. Characterization of all SRC target genes and a proteomic profile of the transcription factors that work with SRCs will provide important insights into the gene networks and pathways used by SRCs to promote carcinogenesis. Third, most in vivo experiments to date have been carried out in knockout mice in which there are certain systemic effects, such as changes in IGF1 activity. It will be important to further assess and validate the roles of SRCs in carcinogenesis by greater use of conditional knockout mice 137, 138 with cell type-specific SRC ablations. In addition, development of stage-specific inactivation (or overexpression) of SRCs in breast and prostate tumours in mice will allow us to determine whether SRCs are stage-dependent therapeutic targets. Finally, the most challenging of all tasks will be to translate the knowledge obtained from basic research to clinical applications and to develop clinically deliverable reagents that can counteract the excessive SRC activities in SRC-promoted cancers.
